Navigation Links
Molecular Imaging Services, Inc. Performs First Rubidium-82 Cardiac PET Scan In Delaware
Date:4/3/2013

WILMINGTON, Del., April 3, 2013 /PRNewswire/ -- Molecular Imaging Services, Inc. (MIS) is pleased to announce that it has performed the first Rubidium-82 Myocardial Perfusion PET scan in its newly opened office at Omega Medical Center located in Newark, Delaware.  Myocardial Perfusion PET Imaging is a powerful tool in the assessment of coronary artery disease (CAD) and has been shown to have clear advantages over conventional SPECT Myocardial Perfusion Imaging. The higher sensitivity, specificity and accuracy of Cardiac PET Imaging can potentially reduce the downstream healthcare costs associated with CAD by decreasing the need for more expensive and higher risk, invasive procedures.

MIS is the first in Delaware to help diagnose heart disease using this advanced imaging technique. "We are excited and extremely pleased to provide access to this technology for the physicians and their patients in our community.  The increased sensitivity, specificity and accuracy of Cardiac PET are well documented making it a powerful diagnostic tool for physicians. We are thrilled to be the first to perform Cardiac PET Perfusion Imaging in Delaware.  MIS also plans to use this PET scanner for brain imaging and research to help advance the field of Molecular Imaging," said Frank DiGregorio , President and CEO of MIS.

About Molecular Imaging Services, Inc.
Headquartered in Wilmington, Delaware, Molecular Imaging Services, Inc. is a privately held company that operates nuclear imaging services nationwide.  With many years of combined experience in the molecular imaging industry, MIS offers nuclear cardiology technologies including SPECT and PET.  For more information, visit www.mismedical.com or send email to info@mismedical.com

 


'/>"/>
SOURCE Molecular Imaging Services, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
5. The 2012 US Molecular Diagnostics Market
6. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
7. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
8. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
9. Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare To Care."
10. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
11. New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... tolerability profile of ropeginterferon alfa-2b versus HU ... long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization in ... this data to the FDA as it seeks approval for ...
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... today that nominations will be accepted from December 5, 2016 through March ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All ... brains of young athletes. Over the course of three years, researchers will study concussions ... guards. The mouth guards, equipped with special sensors, will track the location and force ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a leading ... firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise ... licensing agreement three years ago to design and develop the kathy ireland® Loved ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
Breaking Medicine News(10 mins):